GlassScriptPhysician profile
Olivia Blair
NPI 1982274775
$2,655.46
in general payments reported to CMS, 2019-2025
17 companies · $508 in 2025
The $508 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $794 · 2023: $513 · 2024: $724 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $541.54 | 2021-2023 | Tepezza |
| Ibsa Pharma INC. | $499.04 | 2021-2024 | Tirosint, Tirosint, Licart |
| Amneal Pharmaceuticals LLC | $310.71 | 2021-2025 | Unithroid |
| Novo Nordisk INC | $305.90 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $275.29 | 2024-2025 | Tepezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.92 | 2023-2025 | Xifaxan |
| Lilly USA, LLC | $184.28 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $76.33 | 2025 | Ubrelvy |
| Eisai INC. | $47.15 | 2023-2025 | |
| Madrigal Pharmaceuticals | $46.26 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $24.98 | 2024 | Strensiq |
| Virtus Pharmaceuticals LLC | $22.68 | 2022 | |
| Ardelyx, INC. | $21.92 | 2024 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $18.19 | 2022 | |
| Acella Pharmaceuticals, LLC | $16.17 | 2024 | NP Thyroid 60 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $15.67 | 2023 | Korlym |
| Currax Pharmaceuticals LLC | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.